We established a diversified and comprehensive R&D pipeline covering oncology, autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, ophthalmology, etc.
24
New Molecular Entity drugs marketed in China
4
Other innovative drugs marketed in China
100
In-House Innovative Pharmaceuticals under Clinical Development
400
Ongoing Clinical Studies
20
Ongoing International Clinical Studies
*By Jun, 2025